– Company Expects to Initiate a Phase 1 Study in Late 2020 – “We are excited to advance our ALN-HSD program to the clinic in partnership with Regeneron, particularly given the mass prevalence and high ...
Alnylam Files Clinical Trial Application to Initiate a Phase I Study for ALN-TTRsc, a Subcutaneously
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results